High-density lipoprotein-mediated lutein and zeaxanthin transport

"Lutein and Zeaxanthin transport" is not a single molecular target but rather refers to the physiological process by which these two dietary xanthophyll carotenoids are absorbed from the diet, transported in blood via specific plasma lipoproteins—primarily high-density lipoproteins (HDL) for zeaxanthin and low-density lipoproteins (LDL) for lutein—and delivered to tissues such as the retina. After intestinal absorption facilitated by micellar solubilization with dietary fats, these carotenoids are incorporated into chylomicrons, processed by the liver, then distributed systemically within HDL or LDL particles. Retinal uptake involves further specificity through binding proteins such as scavenger receptor class B type 1 (SR-B1), glutathione S-transferase Pi 1 (GSTP1) for zeaxanthin/meso-zeaxanthin in the macula, and steroidogenic acute regulatory domain protein 3 (StARD3) for lutein[3][5][7][9]. This selective delivery is crucial because higher retinal concentrations of these pigments are associated with protection against age-related macular degeneration due to their antioxidant properties and ability to filter blue light[4][6]. **Note:** "Lutein and Zeaxanthin transport" does not refer to a discrete protein or gene product but rather a complex physiological pathway involving multiple molecular players. Therefore it is **not considered a canonical therapeutic target** like an enzyme or receptor would be. If you seek structured information on specific molecules involved in this process—such as SR-BI/scavenger receptor class B type 1 (SCARB1), ABCA1 transporter, GSTP1 binding protein—those should be listed individually. **Summary judgment:** The entry "Lutein and Zeaxanthin transport" is too broad/vague/incomplete as a molecular target name; it describes a biological process rather than an actionable drug target molecule.[5][7]

Other names

HDL-mediated xanthophyll transportLutein/zeaxanthin plasma transportXanthophyll lipoprotein transport

Not applicable for drugs targeting this "target" directly; mechanism involves passive diffusion or SR-B1-facilitated uptake into enterocytes, packaging into chylomicrons, hepatic repackaging into HDL/LDL particles for systemic distribution[3][9].